Clinical trials recruiting in Verdun, Canada

Phase breakdown

Conditions recruiting in Verdun, Canada

Recruiting trials in Verdun, Canada

• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis
  NCT07786714 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 34 Years · Sex: All (male and female)
• Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia
  NCT07428460 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female)
• Dominantly Inherited Alzheimer Network (DIAN)
  NCT00869817 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Modifying PEST for Psoriatic Arthritis Screening
  NCT06382051 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
  NCT06947993 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Verdun, Canada?

11 recruiting trials have at least one study site in Verdun, Canada.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.